title: Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
abstract: Despite advances in prostate cancer diagnosis and management, morbidity from prostate cancer remains high. Approximately 20% of men present with advanced or metastatic disease, while 29,000 men continue to die of prostate cancer each year. Androgen deprivation therapy (ADT) has been the standard of care for initial management of advanced or metastatic prostate cancer since Huggins and Hodges first introduced the concept of androgen-dependence in 1972, but progression to castration-resistant prostate cancer (CRPC) occurs within 2-3 years of initiation of ADT. CRPC, previously defined as hormone-refractory prostate cancer, is now understood to still be androgen dependent. Multiple mechanisms of resistance help contribute to the progression to castration resistant disease, and the androgen receptor (AR) remains an important driver in this progression. These mechanisms include AR amplification and hypersensitivity, AR mutations leading to promiscuity, mutations in coactivators/corepressors, androgen-independent AR activation, and intratumoral and alternative androgen production. More recently, identification of AR variants (ARVs) has been established as another mechanism of progression to CRPC. Docetaxel chemotherapy has historically been the first-line treatment for CRPC, but in recent years, newer agents have been introduced that target some of these mechanisms of resistance, thereby providing additional survival benefit. These include AR signaling inhibitors such as enzalutamide (Xtandi, ENZA, MDV-3100) and CYP17A1 inhibitors such as abiraterone acetate (Zytiga). Ultimately, these agents will also fail to suppress CRPC. While some of the mechanisms by which these agents fail are unique, many share similarities to the mechanisms contributing to CRPC progression. Understanding these mechanisms of resistance to ADT and currently approved CRPC treatments will help guide future research into targeted therapies.
authors.affiliation: Department of Urology, University of California, Davis, CA, USA.
authors.forename: Thenappan
authors.initials: T
authors.lastname: Chandrasekar
authors.affiliation: Department of Urology, University of California, Davis, CA, USA.
authors.forename: Joy C
authors.initials: JC
authors.lastname: Yang
authors.affiliation: Department of Urology, University of California, Davis, CA, USA.
authors.forename: Allen C
authors.initials: AC
authors.lastname: Gao
authors.affiliation: Department of Urology, University of California, Davis, CA, USA.
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Evans
keywords: Castration-resistant; disease progression; drug resistance; prostatic neoplasms
references.citation: Cell. 2009 Jul 23;138(2):245-56
references.pmid: 19632176
references.citation: Prostate. 2005 Nov 1;65(3):268-75
references.pmid: 16015592
references.citation: Cancer Res. 2013 Jan 15;73(2):483-9
references.pmid: 23117885
references.citation: N Engl J Med. 2014 Mar 6;370(10):970-1
references.pmid: 24597872
references.citation: Prostate. 2008 Dec 1;68(16):1798-805
references.pmid: 18780294
references.citation: CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40
references.pmid: 4625049
references.citation: J Biol Chem. 2011 Oct 14;286(41):36152-60
references.pmid: 21878636
references.citation: Cancer Res. 2006 Mar 1;66(5):2815-25
references.pmid: 16510604
references.citation: Clin Cancer Res. 2005 Jul 1;11(13):4653-7
references.pmid: 16000557
references.citation: BJU Int. 2013 Apr;111(4):672-82
references.pmid: 22897391
references.citation: Proc Natl Acad Sci U S A. 1973 Mar;70(3):765-8
references.pmid: 4514990
references.citation: J Clin Oncol. 2009 Aug 10;27(23 ):3742-8
references.pmid: 19470933
references.citation: Cancer Discov. 2013 Sep;3(9):1030-43
references.pmid: 23842682
references.citation: J Clin Oncol. 2004 Oct 15;22(20):4109-18
references.pmid: 15483020
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: Oncogene. 2004 Oct 18;23(48):7918-27
references.pmid: 15489910
references.citation: Nat Rev Drug Discov. 2014 Feb;13(2):140-56
references.pmid: 24481312
references.citation: Biochim Biophys Acta. 2008 Apr;1785(2):96-132
references.pmid: 18068131
references.citation: Eur J Cancer. 2013 Apr;49(6):1374-403
references.pmid: 23485231
references.citation: J Clin Oncol. 1997 Aug;15(8):2928-38
references.pmid: 9256137
references.citation: Nat Rev Cancer. 2009 Sep;9(9):615-30
references.pmid: 19701241
references.citation: Anticancer Drugs. 2009 Mar;20(3):179-84
references.pmid: 19396016
references.citation: Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12188-93
references.pmid: 18723670
references.citation: Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13728-33
references.pmid: 21795608
references.citation: Cancer Res. 2011 Feb 15;71(4):1208-13
references.pmid: 21285252
references.citation: Hum Mutat. 2012 May;33(5):887-94
references.pmid: 22334387
references.citation: EMBO J. 2011 May 20;30(13):2719-33
references.pmid: 21602788
references.citation: J Clin Invest. 2010 Aug;120(8):2715-30
references.pmid: 20644256
references.citation: Mol Cell Biol. 2001 Dec;21(24):8385-97
references.pmid: 11713275
references.citation: Clin Cancer Res. 2013 Oct 15;19(20):5613-25
references.pmid: 23995860
references.citation: J Urol. 2013 Aug;190(2):429-38
references.pmid: 23665272
references.citation: Adv Exp Med Biol. 2008;617:245-55
references.pmid: 18497048
references.citation: Cancer Biol Ther. 2011 Jan 15;11(2):157-68
references.pmid: 21228626
references.citation: Trends Endocrinol Metab. 2013 Apr;24(4):209-17
references.pmid: 23474062
references.citation: Prog Clin Biol Res. 1979;33:103-11
references.pmid: 93747
references.citation: Oncogene. 2005 Mar 3;24(10 ):1749-66
references.pmid: 15688034
references.citation: Lancet. 2012 Oct 20;380(9851):1419-28
references.pmid: 22698698
references.citation: Cancer Res. 2000 Dec 1;60(23):6590-6
references.pmid: 11118039
references.citation: J Biol Chem. 2010 May 14;285(20):14980-9
references.pmid: 20231295
references.citation: BJU Int. 2008 Aug;102(3):389-97
references.pmid: 18336596
references.citation: Am Soc Clin Oncol Educ Book. 2014;:117-31
references.pmid: 24857068
references.citation: J Clin Oncol. 2002 Jul 1;20(13):3001-15
references.pmid: 12089231
references.citation: Clin Cancer Res. 2011 Sep 15;17 (18):5913-25
references.pmid: 21807635
references.citation: Br J Cancer. 2014 Sep 23;111(7):1249-54
references.pmid: 24867689
references.citation: Cancer Res. 2008 Aug 1;68(15):6407-15
references.pmid: 18676866
references.citation: Front Oncol. 2014 Aug 18;4:222
references.pmid: 25184116
references.citation: Nat Cell Biol. 2007 Oct;9(10):1102-9
references.pmid: 17909521
references.citation: Nat Rev Urol. 2014 Sep;11(9):508-16
references.pmid: 25134829
references.citation: Curr Top Med Chem. 2009;9(15):1479-92
references.pmid: 19860730
references.citation: Nat Clin Pract Urol. 2009 Feb;6(2):76-85
references.pmid: 19198621
references.citation: Oncogene. 2006 Mar 30;25(14):2011-21
references.pmid: 16434977
references.citation: Nat Genet. 1995 Apr;9(4):401-6
references.pmid: 7795646
references.citation: Nat Cell Biol. 2005 Sep;7(9):909-15
references.pmid: 16113678
references.citation: Ann Oncol. 2014 Sep;25(9):1700-9
references.pmid: 24658665
references.citation: Pharmacol Ther. 2013 Dec;140(3):223-38
references.pmid: 23859952
references.citation: J Biol Chem. 2012 Jan 6;287(2):1527-37
references.pmid: 22128178
references.citation: Nat Rev Urol. 2014 Dec;11(12):712-6
references.pmid: 25224448
references.citation: J Biol Chem. 2002 Oct 11;277(41):38087-94
references.pmid: 12163482
references.citation: Br J Cancer. 2009 Sep 15;101(6):951-6
references.pmid: 19690549
references.citation: Curr Opin Pharmacol. 2008 Aug;8(4):440-8
references.pmid: 18674639
references.citation: J Cell Physiol. 2008 Nov;217(2):494-501
references.pmid: 18615564
references.citation: Cancer Res. 2002 Oct 15;62(20):5632-6
references.pmid: 12384515
references.citation: Cancer Discov. 2013 Sep;3(9):1020-9
references.pmid: 23779130
references.citation: N Engl J Med. 2014 Sep 11;371(11):1028-38
references.pmid: 25184630
references.citation: Clin Cancer Res. 2006 Sep 15;12(18):5578-86
references.pmid: 17000695
references.citation: Transl Androl Urol. 2013 Sep 1;2(3):137-147
references.pmid: 25045626
references.citation: J Urol. 1993 Mar;149(3):607-9
references.pmid: 7679759
references.citation: Clin Cancer Res. 2004 Jan 15;10(2):440-8
references.pmid: 14760063
references.citation: Hum Mutat. 2004 Jun;23(6):527-33
references.pmid: 15146455
references.citation: Clin Genitourin Cancer. 2011 Dec;9(2):115-23
references.pmid: 21907635
references.citation: Int J Oncol. 2014 Nov;45(5):1793-801
references.pmid: 25120209
references.citation: Mol Cancer Ther. 2010 Jun;9(6):1831-41
references.pmid: 20501799
references.citation: J Biol Chem. 2010 Feb 12;285(7):5097-105
references.pmid: 20007693
references.citation: Mol Cancer. 2011 Oct 07;10:126
references.pmid: 21982118
references.citation: Ann Oncol. 2014 Feb;25(2):429-34
references.pmid: 24478320
references.citation: Vitam Horm. 1994;49:383-432
references.pmid: 7810074
references.citation: Proc Natl Acad Sci U S A. 2006 May 9;103(19):7264-9
references.pmid: 16651533
references.citation: Best Pract Res Clin Endocrinol Metab. 2013 Aug;27(4):603-16
references.pmid: 24054933
references.citation: Oncogene. 2004 Mar 18;23(12):2197-205
references.pmid: 14767470
references.citation: Nat Rev Cancer. 2001 Oct;1(1):34-45
references.pmid: 11900250
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4543-9
references.pmid: 18628469
references.citation: Clin Cancer Res. 2014 Jun 15;20(12):3198-210
references.pmid: 24740322
references.citation: Mol Endocrinol. 2013 May;27(5):708-14
references.pmid: 23592429
references.citation: Asian J Androl. 2010 Sep;12(5):639-57
references.pmid: 20711217
references.citation: Oncogene. 2008 Oct 23;27(49):6365-75
references.pmid: 18679417
references.citation: Prostate. 2011 Aug 1;71(11):1158-66
references.pmid: 21656826
references.citation: Endocr Rev. 2007 Dec;28(7):778-808
references.pmid: 17940184
references.citation: Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4904-9
references.pmid: 11320241
references.citation: PLoS One. 2011 Apr 28;6(4):e19059
references.pmid: 21552559
references.citation: Mol Cancer Ther. 2013 Sep;12(9):1829-36
references.pmid: 23861346
references.citation: Cancer Res. 2009 Mar 15;69(6):2305-13
references.pmid: 19244107
references.citation: Cancer Cell. 2010 Jul 13;18(1):11-22
references.pmid: 20579941
references.citation: Cancer Res. 2001 Apr 1;61(7):2892-8
references.pmid: 11306464
references.citation: Cell. 2013 Aug 29;154(5):1074-84
references.pmid: 23993097
references.citation: Am J Pathol. 2013 Feb;182(2):460-73
references.pmid: 23219429
references.citation: Cancer Cell. 2010 May 18;17 (5):443-54
references.pmid: 20478527
references.citation: J Biol Chem. 1993 Aug 15;268(23):17404-12
references.pmid: 8394341
references.citation: N Engl J Med. 2014 Jul 31;371(5):424-33
references.pmid: 24881730
references.citation: Br J Cancer. 1999 Sep;81(2):242-51
references.pmid: 10496349
references.citation: Oncotarget. 2014 Sep 15;5(17):7217-59
references.pmid: 25277175
references.citation: N Engl J Med. 2011 May 26;364(21):1995-2005
references.pmid: 21612468
references.citation: Int J Cancer. 2002 Jul 20;100(3):309-17
references.pmid: 12115546
references.citation: Vitam Horm. 1999;55:309-52
references.pmid: 9949684
references.citation: Cancer Res. 2009 Jan 1;69(1):16-22
references.pmid: 19117982
references.citation: Mol Cell Endocrinol. 2012 Sep 5;360(1-2):3-13
references.pmid: 22453214
references.citation: Cancer Res. 2007 Jun 15;67(12):5965-75
references.pmid: 17575167
references.citation: Int J Oncol. 2014 Sep;45(3):919-28
references.pmid: 24969394
references.citation: Trends Endocrinol Metab. 2002 Mar;13(2):55-60
references.pmid: 11854019
references.citation: Cancer Res. 2010 Nov 15;70(22):9253-64
references.pmid: 21045157
references.citation: Nature. 2008 Feb 28;451(7182):1069-75
references.pmid: 18305538
references.citation: Lancet Oncol. 2013 Dec;14(13):1307-16
references.pmid: 24211163
references.citation: Annu Rev Biochem. 1994;63:25-61
references.pmid: 7979239
references.citation: N Engl J Med. 2013 Jan 10;368(2):138-48
references.pmid: 23228172
references.citation: Oncogene. 2014 Sep 4;33(36):4521-30
references.pmid: 24662833
references.citation: Clin Cancer Res. 2004 May 1;10 (9):3169-78
references.pmid: 15131058
references.citation: Oncology (Williston Park). 2009 Jun;23(7):626-30
references.pmid: 19626830
references.citation: Hematol Oncol Clin North Am. 2013 Dec;27(6):1221-41, viii
references.pmid: 24188260
references.citation: Br J Cancer. 2006 Jun 5;94(11):1592-8
references.pmid: 16685278
references.citation: Cancer Res. 2004 Oct 1;64(19):7156-68
references.pmid: 15466214
references.citation: Prostate. 2013 Nov;73(15):1636-50
references.pmid: 23996639
references.citation: Mol Endocrinol. 2010 May;24(5):898-913
references.pmid: 20304998
references.citation: Cell Biol Int. 2010 Jan 25;34(2):177-84
references.pmid: 19947927
references.citation: Neoplasia. 2008 Aug;10(8):897-907
references.pmid: 18670647
references.citation: J Clin Endocrinol Metab. 2012 Feb;97(2):507-16
references.pmid: 22170708
references.citation: Prostate. 1996 Sep;29(3):153-8
references.pmid: 8827083
references.citation: CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
references.pmid: 24399786
references.citation: J Cell Biochem. 2005 Oct 15;96(3):641-52
references.pmid: 16052512
references.citation: Cancer Res. 2008 Jun 1;68(11):4447-54
references.pmid: 18519708
references.citation: Mol Cell. 2005 Sep 2;19(5):631-42
references.pmid: 16137620
references.citation: Mol Cancer Ther. 2013 Aug;12(8):1629-37
references.pmid: 23699654
references.citation: Neoplasia. 2007 Feb;9(2):90-100
references.pmid: 17357254
references.citation: Mol Endocrinol. 2001 Jun;15(6):923-35
references.pmid: 11376111
references.citation: Cancer Res. 2008 Jul 1;68(13):5469-77
references.pmid: 18593950
references.citation: Cancer Res. 2011 Oct 15;71(20):6503-13
references.pmid: 21868758
references.citation: Prostate. 2009 Oct 1;69(14):1579-85
references.pmid: 19575420
references.citation: Mol Cell Biol. 2010 Mar;30(5):1243-53
references.pmid: 20048054
references.citation: Int J Oncol. 2012 May;40(5):1313-20
references.pmid: 22322981
references.citation: Endocr Relat Cancer. 2011 Sep 20;18(5):R183-96
references.pmid: 21778211
references.citation: J Cell Biochem. 2008 Aug 1;104(5):1580-6
references.pmid: 18393355
references.citation: Eur J Cancer. 2003 Sep;39(13):1927-35
references.pmid: 12932673
references.citation: Pharmacogenetics. 2000 Jul;10(5):407-13
references.pmid: 10898110
references.citation: Arch Histol Cytol. 2004 Dec;67(5):417-34
references.pmid: 15781983
references.citation: Nat Cell Biol. 2007 Mar;9(3):347-53
references.pmid: 17277772
references.citation: Cancer Res. 2000 Dec 15;60(24):6841-5
references.pmid: 11156376
references.citation: Endocr Rev. 2005 Jun;26(4):525-82
references.pmid: 15632317
references.citation: J Clin Oncol. 2001 Jan 1;19(1):62-71
references.pmid: 11134196
references.citation: Proc Natl Acad Sci U S A. 2006 May 16;103(20):7789-94
references.pmid: 16682621
references.citation: Cell Death Dis. 2014 Sep 04;5:e1409
references.pmid: 25188519
references.citation: Cancer Manag Res. 2014 Jan 28;6:39-51
references.pmid: 24501545
references.citation: Can Urol Assoc J. 2010 Dec;4(6):380-4
references.pmid: 21191494